Insmed Incorporated (INSM)
| Market Cap | 32.21B +134.6% |
| Revenue (ttm) | 447.02M +30.3% |
| Net Income | -1.18B |
| EPS | -6.22 |
| Shares Out | 213.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,882,504 |
| Open | 152.44 |
| Previous Close | 152.44 |
| Day's Range | 150.34 - 156.52 |
| 52-Week Range | 60.40 - 212.75 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 192.27 (+27.31%) |
| Earnings Date | Feb 19, 2026 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]
Financial Performance
In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $192.27, which is an increase of 27.31% from the latest price.
News
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch
Insmed remains a compelling buy after an ~30% pullback, as Brinsupri's blockbuster launch trajectory outpaces initial expectations. Brinsupri delivered $144.6M in Q4 sales and 11,550 patient starts in...
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (R...
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmona...
Artisan Small Cap Fund Q4 2025 Portfolio Activity
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investme...
Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity
The portfolio delivered a modest negative absolute return during Q4 but outpaced the Russell Midcap® Growth Index by several percentage points. IT was an area of strength during the quarter, led by ho...
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed CEO Will Lewis talks its rare disease drug pipeline
Will Lewis, Insmed CEO, joins 'Fast Money' to talk the rare disease pipeline, acquisitions in the pharma space, and more.
Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances
Insmed Inc (NASDAQ: INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launche...
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
— BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome in...
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $INSM--INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm.
Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news
Mizuho's Jared Holz joins 'Fast Money' to talk Insmed shares tanking on discontinuing development of sinus drug.
Why Is Insmed Stock Falling Thursday?
Insmed Incorporated (NASDAQ: INSM) stock plunged on Thursday.
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.
Insmed Stock Plummets 19%. This Is What Sparked the Selloff.
The biopharmaceutical company said it was discontinuing development of a drug treating a chronic sinus condition.
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Insmed scraps development of sinus drug after mid-stage study failure
Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage study, sending...
Insmed Provides Clinical and Business Update
—Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquires Phas...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
— Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting N...
Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript
Insmed Incorporated ( INSM) Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM EST Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Yuxi ...